ArticleBMC psychiatry2026
Plasma SERPINA3 and its clinical correlates in adolescent major depressive disorder: an exploratory case-control study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajor depressive disorder (MDD) in adolescents lacks objective peripheral biomarkers that may assist diagnosis and biological stratification. Serine protease inhibitor A3 (SERPINA3) is an inflammation-related acute-phase protein, but its circulating levels and clinical relevance in adolescent MDD remain unclear.
methodsIn this exploratory case-control study, 141 adolescents with MDD and 76 healthy controls were enrolled. Plasma SERPINA3 concentrations were measured by enzyme-linked immunosorbent assay. Within the MDD cohort, participants were stratified at the median SERPINA3 concentration (380 pg/mL) for exploratory subgroup analyses. Associations between SERPINA3 and laboratory variables were examined using exploratory correlation and regression analyses. P values for the exploratory laboratory comparisons in Table 2 were adjusted using the Benjamini-Hochberg false discovery rate (FDR) procedure. Receiver operating characteristic (ROC) analysis was used to assess the discriminatory performance of SERPINA3, with internal validation by 2000 bootstrap resamples and stratified 10-fold cross-validation.
resultsPlasma SERPINA3 concentrations were higher in adolescents with MDD than in healthy controls (P < 0.0001). Several laboratory variables showed nominal between-group differences in unadjusted analyses, but none remained statistically significant after FDR correction (all q ≥ 0.242). In exploratory multivariable analyses, Glucose, RDW-CV, and indirect bilirubin were associated with continuous SERPINA3 concentration. In the full-sample ROC analysis, the AUC was 0.8433 and the optimal cutoff was 309 pg/mL. Internal validation yielded an optimism-corrected AUC of 0.8421 in bootstrap resampling and a mean test AUC of 0.8393 in stratified 10-fold cross-validation.
conclusionsIn this exploratory case-control study, plasma SERPINA3 concentrations were higher in adolescents with MDD than in healthy controls. However, the observed laboratory associations were not robust after correction for multiple testing, and the discriminatory performance should be interpreted as preliminary and internally validated only within this cohort. These findings are hypothesis-generating and require confirmation in larger, longitudinal, and independent cohorts. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.